hyaluronidase injected intradermally
Phase 1Small molecule
hyaluronidase injected intradermally is one of 36 small molecule programs targeting Skin Disease. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
45 competitors in Skin Disease
#DrugCompanyPhaseTrials
1Ilumya
Sun Pharmaceutical Industries, Inc.Approved
Zyvox
PfizerApproved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Stromectol
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Allegra
CChattem
Approved
Tygacil
PPrism Pharmaceuticals
Approved
Kenalog
BBausch Health Americas, Inc.
Approved
Cubicin
BBaxter Healthcare Corporation
Approved
Xylocaine
MMEDRx USA, Inc.
Approved
Levaquin
WWim Janssens
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Skin Disease1 trial
Hyaluronidase in Treating Oral Microstomia in Patients With Sclerosing Skin Disease
Withdrawn·—·Phase 1·NCT04656704
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- BBrigham and Women's Hospital